246 related articles for article (PubMed ID: 37444389)
1. B7-H3 in Pediatric Tumors: Far beyond Neuroblastoma.
Bottino C; Vitale C; Dondero A; Castriconi R
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444389
[TBL] [Abstract][Full Text] [Related]
2. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
[TBL] [Abstract][Full Text] [Related]
3. B7-H3-targeted CAR-T cell therapy for solid tumors.
Li G; Wang H; Wu H; Chen J
Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
[TBL] [Abstract][Full Text] [Related]
4. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
Guo X; Chang M; Wang Y; Xing B; Ma W
Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196
[TBL] [Abstract][Full Text] [Related]
5. Hopes on immunotherapy targeting B7-H3 in neuroblastoma.
Pulido R; Nunes-Xavier CE
Transl Oncol; 2023 Jan; 27():101580. PubMed ID: 36327699
[TBL] [Abstract][Full Text] [Related]
6. Targeting B7-H3-A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment.
Rasic P; Jeremic M; Jeremic R; Dusanovic Pjevic M; Rasic M; Djuricic SM; Milickovic M; Vukadin M; Mijovic T; Savic D
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110590
[TBL] [Abstract][Full Text] [Related]
7. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G
Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.
Lichtman EI; Du H; Shou P; Song F; Suzuki K; Ahn S; Li G; Ferrone S; Su L; Savoldo B; Dotti G
Clin Cancer Res; 2021 Jun; 27(11):3141-3153. PubMed ID: 33531429
[TBL] [Abstract][Full Text] [Related]
9. Targeting B7-H3 Immune Checkpoint With Chimeric Antigen Receptor-Engineered Natural Killer Cells Exhibits Potent Cytotoxicity Against Non-Small Cell Lung Cancer.
Yang S; Cao B; Zhou G; Zhu L; Wang L; Zhang L; Kwok HF; Zhang Z; Zhao Q
Front Pharmacol; 2020; 11():1089. PubMed ID: 32848731
[TBL] [Abstract][Full Text] [Related]
10. B7-H3-Targeting Chimeric Antigen Receptors Epstein-Barr Virus-specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3-positive Solid Tumors.
Yeo SP; Kua L; Tan JW; Lim JK; Wong FH; Santos MD; Poh CM; Goh AX; Koh XY; Zhou X; Rajarethinam R; Chen Q; Her Z; Horak ID; Low L; Tan KW
Cancer Res Commun; 2024 Jun; 4(6):1410-1429. PubMed ID: 38717140
[TBL] [Abstract][Full Text] [Related]
11. A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers.
Birley K; Leboreiro-Babe C; Rota EM; Buschhaus M; Gavriil A; Vitali A; Alonso-Ferrero M; Hopwood L; Parienti L; Ferry G; Flutter B; Himoudi N; Chester K; Anderson J
Mol Ther Oncolytics; 2022 Sep; 26():429-443. PubMed ID: 36159778
[TBL] [Abstract][Full Text] [Related]
12. B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models.
Huang B; Luo L; Wang J; He B; Feng R; Xian N; Zhang Q; Chen L; Huang G
Oncoimmunology; 2020; 9(1):1684127. PubMed ID: 32002297
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.
Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W
J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349
[TBL] [Abstract][Full Text] [Related]
14. New Emerging Targets in Cancer Immunotherapy: The Role of B7-H3.
Koumprentziotis IA; Theocharopoulos C; Foteinou D; Angeli E; Anastasopoulou A; Gogas H; Ziogas DC
Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250867
[TBL] [Abstract][Full Text] [Related]
15. B7-H3 immunoregulatory roles in cancer.
Mortezaee K
Biomed Pharmacother; 2023 Jul; 163():114890. PubMed ID: 37196544
[TBL] [Abstract][Full Text] [Related]
16. B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors.
Zhang Z; Jiang C; Liu Z; Yang M; Tang X; Wang Y; Zheng M; Huang J; Zhong K; Zhao S; Tang M; Zhou T; Yang H; Guo G; Zhou L; Xu J; Tong A
Mol Ther Oncolytics; 2020 Jun; 17():180-189. PubMed ID: 32346608
[TBL] [Abstract][Full Text] [Related]
17. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
Picarda E; Ohaegbulam KC; Zang X
Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
[TBL] [Abstract][Full Text] [Related]
18. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors.
Lei X; Ou Z; Yang Z; Zhong J; Zhu Y; Tian J; Wu J; Deng H; Lin X; Peng Y; Li B; He L; Tu Z; Chen W; Li Q; Liu N; Zhang H; Wang Z; Fang Z; Yamada T; Lv X; Tian T; Pan G; Wu F; Xiao L; Zhang L; Cai T; Wang X; Tannous BA; Li J; Kontos F; Ferrone S; Fan S
Clin Cancer Res; 2021 Jul; 27(13):3757-3771. PubMed ID: 33811153
[TBL] [Abstract][Full Text] [Related]
19. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
[No Abstract] [Full Text] [Related]
20. B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model.
Zhang S; Black RG; Kohli K; Hayes BJ; Miller C; Koehne A; Schroeder BA; Abrams K; Schulte BC; Alexiev BA; Heimberger AB; Zhang A; Jing W; Ng JCK; Shinglot H; Seguin B; Salter AI; Riddell SR; Jensen MC; Gottschalk S; Moore PF; Torok-Storb B; Pollack SM
Mol Cancer Ther; 2022 Jun; 21(6):999-1009. PubMed ID: 35405743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
